YC Application for Healthcare Startups — What to Include

This page covers exactly what to include in each section of a healthcare YC application, with frameworks specific to clinical products, healthtech infrastructure, consumer health, and digital therapeutics.

1. Do you understand who actually pays?

Healthcare has one of the most complex payment structures of any industry — patients, insurers, employers, providers, and government payers each pay differently and have different incentives. Partners want to see that you have identified your specific payer and understand their incentive structure, not a vague "patients will pay for better health."

2. Have you validated with the actual clinical or operational stakeholder?

A product that looks compelling to a consumer or a tech-savvy outsider may fail completely with the actual clinical workflow it needs to integrate into. Partners want evidence of validation with the specific person who would use or approve your product inside a real healthcare setting — a physician, a nurse, a hospital administrator, a health plan medical director.

3. What is your regulatory classification and pathway?

Are you a medical device requiring FDA clearance, a wellness product with no regulatory pathway, clinical decision support software, or something in between? Partners want a clear, specific answer — not avoidance of the question.

4. How long is your actual sales cycle, and have you accounted for it?

Healthcare enterprise sales cycles (to hospitals, health systems, insurers) routinely run 6-18 months. Consumer health sales cycles face different but equally real friction — skepticism, habit formation, and competition with free alternatives. Partners want to see realistic expectations, not generic SaaS growth assumptions applied to healthcare.

5. Is there evidence of clinical or behavioral outcome, not just engagement?

A health product that people use frequently but that does not produce a measurable health outcome (symptom improvement, behavior change, cost reduction, diagnostic accuracy) has not yet proven the thing healthcare buyers actually care about.

50-Character Description

Formula: [Health function] for [specific patient/provider population]

Strong examples:

• "Remote glucose monitoring for diabetic patients"
• "AI clinical documentation for emergency physicians"
• "Mental health teletherapy for Indian college students"
• "Medication adherence platform for chronic disease patients"

Avoid: "healthcare platform," "digital health solution," anything that does not specify the actual clinical function and the specific population served.

Product Description (~150 words)

Structure: Population → clinical/operational problem → your mechanism → payer/regulatory context → current evidence

"[Population] experiences [specific clinical or operational problem with measurable cost]. We provide [specific mechanism] that [specific clinical or workflow outcome]. We are [regulatory classification] and are paid by [specific payer]. We currently have [X] patients/providers using the product with [specific outcome metric]."

Example:

"Patients with Type 2 diabetes in tier 2 India have limited access to continuous glucose monitoring and rely on infrequent finger-prick tests that miss dangerous glucose excursions. We provide a low-cost continuous glucose monitor paired with an app that alerts patients and their physician to dangerous trends in real time. We are classified as a Class B medical device under India's CDSCO framework and are reimbursed through partnerships with 3 regional insurers. We currently monitor 240 patients with a 34% reduction in HbA1c among those active for 6+ months."

The Payer Field

Be explicit and specific about who pays and why they are motivated to pay:

"Our primary payer is the patient directly at ₹999/month, since insurance reimbursement for continuous glucose monitoring is not yet standard in India. We are in active discussions with 2 regional insurers about including our device in their diabetes management riders, which would reduce patient-borne cost and significantly expand our addressable market."

If you are B2B2C (selling through providers or health systems): "We sell to hospital diabetes clinics at ₹40,000/month per clinic, covering up to 200 patients. The clinic's incentive is reduced readmission penalties under their value-based care contracts — our pilot data shows a 22% reduction in diabetes-related ER visits."

The Regulatory Classification Field

State your regulatory status precisely:

"We are classified as a Class B medical device under India's CDSCO Medical Device Rules, requiring a manufacturing license and post-market surveillance, which we have obtained. We are not currently pursuing FDA clearance as our initial market is India-only."

If you are not a regulated device: "Our product is wellness software, not a regulated medical device — we explicitly avoid making diagnostic or treatment claims, and our terms of service and marketing materials have been reviewed by regulatory counsel to confirm this classification."

If your regulatory status is unresolved: "We believe our product falls into [specific classification] but have not yet completed formal regulatory consultation. We are engaging counsel before our next product iteration to confirm our classification before any clinical claims expand."

The Clinical Validation Field

Distinguish between engagement evidence and outcome evidence explicitly:

"Beyond engagement (78% of patients log data 5+ days/week), we have outcome data: HbA1c reduction of 0.8 percentage points on average among patients active for 6+ months, validated against a control group of patients on standard care. This data comes from our pilot with [specific clinic], not from self-reported outcomes."

The Sales Cycle and Distribution Field

Be realistic about healthcare-specific sales dynamics:

"Our sales cycle to hospital systems is 4-6 months, including a clinical pilot phase before contract signing. We have shortened this by starting with department-level pilots (single diabetes clinics) rather than full hospital system contracts, which cuts the cycle to 6-8 weeks for initial pilot agreement."

Clinical/provider-facing products:

• Time to clinical pilot agreement (shorter signals stronger product-market fit with the actual buyer)
• Clinical outcome data versus engagement-only data (outcome data is weighted far more heavily)
• Physician/clinician retention and usage rate within the workflow (not just initial adoption)

Consumer health products:

• Day-30 and Day-90 retention (healthcare habit formation requires longer windows than typical consumer apps)
• Behavior change or symptom improvement evidence, not just app engagement
• Conversion from free/trial to paid, accounting for healthcare's typically higher trust threshold

Healthtech infrastructure/B2B:

• Number of integrated health systems, EHR platforms, or payer partnerships
• Data processing volume and accuracy metrics specific to the clinical use case
• Time-to-integration with new partners

Digital therapeutics/regulated products:

• Clinical trial status and results if applicable
• FDA or equivalent regulatory pathway progress (510(k) submitted, breakthrough designation, etc.)
• Reimbursement pathway clarity (CPT code assignment, payer coverage decisions)

Failure 1: Engagement metrics presented as outcome metrics

"Patients use our app 4 times per week" is engagement. "Patients using our app for 90+ days show a 15% reduction in emergency room visits" is outcome. Healthcare buyers and YC partners reading healthcare applications both know this distinction, and applications that conflate the two signal either inexperience with the category or an attempt to obscure weak outcome data.

Failure 2: Underestimating the sales cycle and projecting SaaS-speed growth

A founder who projects 20% MoM growth for a product that requires hospital procurement cycles has not internalized how healthcare enterprise sales actually work. Realistic, healthcare-specific growth projections are more credible than generic SaaS benchmarks applied to a fundamentally different buying process.

Failure 3: No clear regulatory position

Avoiding the regulatory classification question, or describing your product in a way that suggests you have not determined whether you are making regulated medical claims, is one of the fastest ways to lose credibility in a healthcare application. Regulatory ambiguity in this category is a business-ending risk, not a minor administrative detail.

Failure 4: Validating with the wrong stakeholder

Building a healthcare product based on consumer or founder intuition without validating with the actual clinical decision-maker (a physician who would prescribe or recommend it, a hospital administrator who would approve purchasing it) often produces a product that is compelling in theory but does not fit the real clinical workflow.

Failure 5: No clarity on who actually pays

Healthcare's multi-payer complexity means "people will pay for better health" is not a business model. The strongest healthcare applications name the specific payer (patient out-of-pocket, insurer, employer, government program, hospital system) and explain that payer's specific incentive to pay.

If you do not have a clinical background, your application needs to demonstrate that you have done the work to compensate for it — extensive interviews with physicians or relevant clinical stakeholders, a clinical advisor with relevant credentials, and validation that goes beyond what a patient or consumer perspective alone could reveal. Name your clinical advisors specifically and describe what they have contributed to product decisions, not just their titles.